Swedish pharmaceutical companies Moberg Pharma AB (OMX: MOB) and Allderma announced on Monday that the launch of Terclara (MOB-015) has commenced in Norway, following its successful market-leading debut in Sweden. This expansion is a strategic milestone for both companies, leveraging Swedish market experience to strengthen their footprint in Scandinavia.

Terclara® is a novel topical treatment for onychomycosis, with market approval in 13 EU countries. The launch in Norway was made possible by Moberg Pharma's qualification of a new terbinafine supplier, announced on 18 December 2024. Initial pharmacy deliveries are expected in February 2025, accompanied by educational campaigns for healthcare professionals and intensified consumer marketing ahead of peak demand.

Stockholm-headquartered Moberg Pharma specializes in commercialising proprietary drug delivery innovations and has conducted Phase 3 trials for MOB-015 involving over 800 patients. With agreements in Europe and Canada, the company is positioned to lead the nail fungus treatment market.

Allderma Pharmaceuticals, founded in 2001, focuses on dermatology and self-care solutions. Known for investing in healthcare education and dermatological research, the company has been part of 3iM Invest AB's Consumer Healthcare portfolio since 2020.